For the latest COVID-19 information, visit vcuhealth.org/covid-19 or Children’s Hospital of Richmond at VCU for pediatrics. For vaccine details, visit vcuhealth.org/covidvaccine.
Need help
Locations
It’s important for patients experiencing uterine fibroids to weigh their treatment options carefully. If you have any questions or concerns regarding the procedure, please call the VCU Uterine Fibroid Embolization hotline at (804) 828-4914.
Uterine fibroids are benign, noncancerous growths within or on the muscular walls of the uterus that range in size from ¼-inch to the size of a cantaloupe. They are relatively common and affect 20 percent to 40 percent of women of child-bearing age.
Uterine fibroid embolization is an alternative to traditional treatments that include the surgical removal of the fibroids (myomectomy) or removal of the entire uterus (hysterectomy). UFE blocks the blood supply to the fibroids, causing them to shrink. It is a minimally invasive procedure and is clinically proven to be successful in reducing the major symptoms of fibroids.
UFE may be appropriate for patients who meet the following criteria:
While UFE is an effective, non-invasive option for some women, it may not be for all patients, including those who have:
There are several advantages offered by the UFE procedure:
UFE may also allow maintenance of fertility. Several studies have shown that women have become pregnant and given birth to healthy babies after undergoing UFE.
There are a few risks associated with UFE, including:
Most insurance companies cover UFE.
A majority of UFE patients experience an improvement in bleeding and pelvic pain, as well as bowel, bladder or pelvic fullness.
Within three to six months, you should notice a 50 percent reduction in the size of your fibroids, and an 80 percent reduction after the first year. Overall, you should experience a 90 percent improvement of your symptoms.